Prostate Cancer Active Surveillance Decision Aid

This prostate cancer active surveillance decision aid helps you see whether careful monitoring - rather than immediate surgery or radiation - is a guideline-supported option for your diagnosis. Answer three questions about your Grade Group, PSA, and stage, and it maps you to your NCCN risk group with a clear, evidence-based recommendation. It is built for men already diagnosed who are weighing their next step. Start in our prostate health hub.

Medically reviewed by

Dr. Muhammad Khalid

MBBS, FCPS (Urology), MCPS (Gen. Surgery), CHPE, CRSM · IMC #539472

Last updated

July 22, 2026

ValidatedNCCN risk groups

Used WorldwideNCCN, AUA & EAU aligned

PrivateNothing is stored or sent

prostate cancer Active Surveillance Decision Aid

The Tool

Related Prostate Tools

Decision Tool Gleason Score Risk Interpreter Turn your Grade Group into plain-language risk. Open Tool → Calculator Prostate Cancer Risk Calculator Estimate your risk band before a biopsy decision. Open Tool → Calculator PSA Age-Adjusted Interpreter See what your PSA means for a man your age. Open Tool → Calculator PSA Velocity Tracker Track how fast your PSA is changing over time. Open Tool → Decision Tool PI-RADS + PSA Density Biopsy Decision Weigh your MRI score and density before a biopsy. Open Tool → Calculator PSA Density Calculator Divide PSA by prostate volume for a sharper signal. Open Tool →

Full Clinical Guide

In This Guide:

Key Takeaways

Active surveillance is a structured monitoring plan for low-risk prostate cancer – not “doing nothing.”
Your Grade Group (Gleason score) is the biggest factor; PSA and stage refine it.
For very-low and low-risk cancer, NCCN and AUA name surveillance the preferred first choice.
This aid needs a confirmed biopsy grade – it is for men already diagnosed, not for screening.

What This Active Surveillance Decision Aid Measures

This active surveillance decision aid translates your prostate cancer diagnosis into the same risk language your urologist uses. It maps three facts from your pathology and blood work – your Grade Group (Gleason score), your PSA, and your clinical stage – onto the NCCN risk groups, the stratification system that underpins modern prostate cancer guidelines [1][2]. It is built for men who already have a biopsy-confirmed diagnosis and are weighing whether to monitor the cancer or treat it now. It does not screen for cancer and it does not replace your specialist; it organizes what you already know so the conversation about active surveillance starts from the right footing.

How Your Risk Group Decides the Recommendation

Grade Group is the single strongest driver. Grade Group 1 (Gleason 6) behaves so indolently that it rarely spreads, which is why surveillance dominates that group; Grade Group 4-5 (Gleason 8-10) behaves aggressively, which is why it almost never does. PSA and stage refine the picture in between. The decisive middle category is favorable intermediate-risk – a single intermediate feature, Grade Group 1 or 2, with under half the biopsy cores involved – where surveillance is offered to selected men rather than as a default [3]. Think of it as a sieve: grade sorts the coarse buckets, then PSA, core burden, and PSA density settle the borderline cases. If you want to understand the grade itself first, our Gleason Score Risk Interpreter walks through what each pattern means.

Grade sorts the coarse buckets; PSA density and core count settle the borderline ones. A single label like “Grade Group 2” can describe two very different cancers.

Reading Your Recommendation

The aid lands on one of three messages. Surveillance preferred means your cancer is very-low or low-risk and guidelines back monitoring as the first choice – the long-term ProtecT trial found that men with low-risk disease who chose monitoring had very similar prostate cancer survival to those treated immediately, with a somewhat higher chance the cancer spreads over the years [4][5]. Depends on the details means you are in the favorable-intermediate or borderline zone, where your PSA density and core count decide it. Treatment recommended means the grade or stage has crossed into the range where watching carries real risk, and definitive treatment is standard. A confirmatory MRI often shifts a borderline result before any final choice is made.

A recommendation to treat is about timing a curable cancer – not a hopeless one – and a recommendation to monitor is an active choice backed by long-term trials, not a delay.

What to Do With Your Result

If surveillance is preferred, your job is to make monitoring concrete: confirm the risk group, lock in a PSA and biopsy schedule, and learn the triggers that would change the plan. If your result depends on the details, get the exact numbers – PSA density, positive-core count – in writing, because they decide which way you fall. If treatment is recommended, the next move is staging and meeting both a surgeon and a radiation oncologist before you choose. Wherever you land, knowing your own numbers changes the conversation; the PSA Age-Adjusted Interpreter helps you put your PSA in context first.

If you are unsure about your result, the PDF report this tool generates gives you a ready-made framework to bring to your next appointment.

In My Practice

“The first confirmatory biopsy – usually within a year of starting surveillance – tells me more about whether monitoring fits than any single PSA reading. Some men are reclassified upward and the plan changes; many simply confirm a low-grade cancer and settle into monitoring for years. I ask men to treat that first year as the real test, not the day of diagnosis.”

Surveillance is judged over the first year of monitoring, not decided in a single clinic visit.

References

NCCN Guidelines Insights: Prostate Cancer, Version 3.2024. Journal of the NCCN. Risk stratification; active surveillance preferred for very-low and low-risk disease.
Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II – Principles of Active Surveillance. J Urol 2022;208:19-25. Journal of Urology.
Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I – Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208:10-18. Journal of Urology. Favorable intermediate-risk definition.
EAU Guidelines on Prostate Cancer. European Association of Urology. uroweb.org. Risk-adapted management and surveillance criteria.
Hamdy FC, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-1558. PubMed. The ProtecT trial.

Frequently Asked Questions

Does active surveillance mean my prostate cancer goes untreated?

No. Active surveillance is close monitoring with the intent to treat if the cancer shows signs of progressing. You stay on a schedule of PSA tests, clinic reviews, MRI, and repeat biopsies, and you move to surgery or radiation if the grade rises. It is chosen precisely because low-risk prostate cancer rarely needs immediate treatment – not because treatment is being withheld. Our Gleason Score Risk Interpreter explains the grade that drives this.

What is the difference between active surveillance and watchful waiting?

They sound alike but differ in intent. Active surveillance is for men fit for treatment: it monitors closely and aims to cure if the cancer progresses. Watchful waiting is for men whose age or health means treatment would do more harm than good; it manages symptoms only if they appear, without the intent to cure. The tool above assumes you are a surveillance candidate, not a watchful-waiting one.

Can I switch to treatment later if my cancer changes or I change my mind?

Yes, and that option is the whole point. Surveillance is designed so that a rise in grade on repeat biopsy, or a clear change on MRI, moves you to treatment while the cancer is still curable. Many men stay on monitoring for years; others switch when the picture changes. You can also choose treatment at any time for peace of mind. Read more on how active surveillance works.

How accurate is this tool, and can I rely on it?

This aid applies published NCCN risk groups and AUA active surveillance principles to the details you enter, so it is only as accurate as those details – your Grade Group, PSA, and stage must come from your actual pathology and staging reports. It is an educational screening aid, not a diagnosis, and it cannot see your MRI, your full biopsy, or your medical history. Treat its output as a structured starting point for a specialist conversation, never as a final decision.

How do I use this result at my doctor’s appointment?

Use the Download My Report button to generate a two-page PDF summarizing your answers, your risk-group result, and a set of questions to ask. Bring it to your urologist or oncologist so the discussion starts from your specific numbers rather than general worry. The questions are written to surface the real decision points – your exact risk group, whether an MRI or confirmatory biopsy is needed, and what would trigger a change in plan.

Dr. Muhammad Khalid

MBBS · FCPS (Urology) · MCPS (Gen. Surgery) · CHPE · CRSM · IMC #539472

Specialist urologist with 11+ years of clinical experience across tertiary teaching hospitals. Trained at Lady Reading Hospital and Khyber Teaching Hospital, Peshawar. Author of 5 peer-reviewed international publications in Cureus, WJSA, and AJBS. Procedural expertise: URS, PCNL, RIRS, TURP, TURBT, and major open urological surgery. Full profile →

This article is for educational purposes only and does not constitute medical advice. Always consult your physician or urologist for diagnosis and treatment decisions specific to your condition.